

(51) International Patent Classification 5 : C07K 15/06, C12N 15/12 A61K 37/02		A1	(11) International Publication Number: WO 92/07004 (43) International Publication Date: 30 April 1992 (30.04.92)
(21) International Application Number:	PCT/US91/07654		(74) Agent: PITCHER, Edmund, R.; Testa, Hurwitz & Thibeault, Exchange Place, 53 State Street, Boston, MA 02109-2809 (US).
(22) International Filing Date:	18 October 1991 (18.10.91)		
(30) Priority data: 600,024	18 October 1990 (18.10.90)	US	(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).
(71) Applicant: CREATIVE BIOMOLECULES, INC. [US/US]; 35 South Street, Hopkinton, MA 01748 (US).			
(72) Inventors: OZKAYNAK, Engin ; 44 Purdue Drive, Milford, MA 01757 (US). OPPERMANN, Hermann ; 25 Summer Hill Road, Medway, MA 02053 (US). KUBER-ASAMPATH, Thangavel ; 6 Spring Street, Medway, MA 02053 (US). RUEGER, David, C. ; 150 Edgemere Road, Apt. 4, West Roxbury, MA 02132 (US).			

(54) Title: OSTEOGENIC PROTEIN**(57) Abstract**

Disclosed are 1) the cDNA and amino acid sequence for a murine polypeptide chain, mOP-1, useful in dimeric osteogenic proteins, 2) methods of producing osteogenic proteins using recombinant technology, 3) methods of producing osteogenic devices comprising mOP-1 dispersed in xenogenic bone matrices, and 4) use of the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

Osteogenic Protein

Background of the Invention

5

This invention relates to a novel polypeptide chain and to osteogenic proteins comprising this polypeptide chain which are capable of inducing osteogenesis in mammals, to a gene encoding the polypeptide chain, to 10 methods for its production using recombinant DNA techniques, and to bone and cartilage repair procedures using the dosteogenic proteins.

Mammalian bone tissue is known to contain one or 15 more proteinaceous materials, presumably active during growth and natural bone healing, which can induce a developmental cascade of cellular events resulting in endochondral bone formation. This active factor (or factors) has variously been referred to in the 20 literature as bone morphogenetic or morphogenic protein, bone inductive protein, osteogenic protein, osteogenin, or osteoinductive protein.

The developmental cascade of bone differentiation 25 consists of recruitment of mesenchymal cells, proliferation of progenitor cells, calcification of cartilage, vascular invasion, bone formation, remodeling, and finally marrow differentiation (Reddi (1981) Collagen Rel. Res. 1:209-226).

30

Though the precise mechanisms underlying these phenotypic transformations are unclear, it has been shown that the natural endochondral bone

dissociatively extracted and reconstituted with inactive residual collagenous matrix to restore full bone induction activity (Sampath and Reddi, (1981) Proc. Natl. Acad. Sci. USA 78:7599-7603). This
05 provides an experimental method for assaying protein extracts for their ability to induce endochondral bone in vivo. Several species of mammals produce closely related protein as demonstrated by cross species implant experiments (Sampath and Reddi (1983) Proc.
10 Natl. Acad. Sci. USA 80:6591-6595).

The potential utility of these proteins has been recognized widely. It is contemplated that the availability of the protein would revolutionize orthopedic medicine, certain types of plastic surgery,
15 and various periodontal and craniofacial reconstructive procedures.

The observed properties of these protein fractions have induced an intense research effort in various laboratories directed to isolating and identifying the
20 pure factor or factors responsible for osteogenic activity. The current state of the art of purification of osteogenic protein from mammalian bone is disclosed by Sampath et al. (1987) Proc. Natl. Acad. Sci. USA 84: 7109-7113. Urist et al. (1984) Proc. Soc. Exp. Biol.
25 Med. 173: 194-199 disclose a human osteogenic protein fraction which was extracted from demineralized cortical bone by means of a calcium chloride-urea inorganic-organic solvent mixture, and retrieved by differential precipitation in guanidine-hydrochloride
30 and preparative gel electrophoresis. The authors report that the protein fraction has an amino acid composition of an acidic polypeptide and a molecular weight in a range of 17-18 kD.

Urist et al. (1984) Proc. Natl. Acad. Sci. USA 81: 371-375 disclose a bovine bone morphogenetic protein extract having the properties of an acidic polypeptide and a molecular weight of approximately 18 kD. The 05 authors reported that the protein was present in a fraction separated by hydroxyapatite chromatography, and that it induced bone formation in mouse hindquarter muscle and bone regeneration in trephine defects in rat and dog skulls. Their method of obtaining the extract 10 from bone results in ill-defined and impure preparations.

European Patent Application Serial No. 148,155, published October 7, 1985, purports to disclose osteogenic proteins derived from bovine, porcine, and 15 human origin. One of the proteins, designated by the inventors as a P3 protein having a molecular weight of 22-24 kD, is said to have been purified to an essentially homogeneous state. This material is reported to induce bone formation when implanted into 20 animals.

International Application No. PCT/087/01537, published January 14, 1988, discloses an impure fraction from bovine bone which has bone induction qualities. The named applicants also disclose putative 25 "bone inductive factors" produced by recombinant DNA techniques. Four DNA sequences were retrieved from human or bovine genomic or cDNA libraries and expressed in recombinant host cells. While the applicants stated that the expressed proteins may be bone morphogenic 30 proteins, bone induction was not demonstrated, suggesting that the recombinant proteins are not osteogenic. The same group reported subsequently

(Science 242:1528, Dec, 1988) that three of the four factors induce cartilage formation, and postulate that bone formation activity "is due to a mixture of regulatory molecules" and that "bone formation is most 05 likely controlled ... by the interaction of these molecules." Again, no bone induction was attributed to the products of expression of the cDNAs. See also Urist et al., EP0,212,474 entitled Bone Morphogenic Agents.

10 Wang et al. (1988) Proc. Nat. Acad. Sci. USA 85: 9484-9488 discloses the purification of a bovine bone morphogenetic protein from guanidine extracts of demineralized bone having cartilage and bone formation activity as a basic protein corresponding to a 15 molecular weight of 30 kD determined from gel elution. Purification of the protein yielded proteins of 30, 18 and 16 kD which, upon separation, were inactive. In view of this result, the authors acknowledged that the exact identity of the active material had not been 20 determined.

Wang et al. (1990) Proc. Nat. Acad. Sci. USA 87: 2220-2227 describes the expression and partial purification of one of the cDNA sequences described in PCT 87/01537. Consistent cartilage and/or bone 25 formation with their protein requires a minimum of 600 ng of 50% pure material.

International Application No. PCT/89/04458 published April 19, 1990 (Int. Pub. No. WO90/003733), describes the purification and analysis of a family of 30 osteogenic factors called "P3 OF 31-34". The protein family contains at least four proteins, which are characterized by peptide fragment sequences. The

impure mixture P3 OF 31-34 is assayed for osteogenic activity. The activity of the individual proteins is neither assessed nor discussed.

It is an object of this invention to provide novel
05 polypeptide chains useful as subunits of dimeric
osteogenic proteins capable of endochondral bone
formation in allogenic and xenogenic implants in
mammals, including humans. Another object is to
10 provide genes encoding these polypeptide chains and to
provide methods for the production of osteogenic
proteins comprising these polypeptide chains using
recombinant DNA techniques, as well as to provide
antibodies capable of binding specifically to epitopes
on these proteins.

15 These and other objects and features of the
invention will be apparent from the description,
drawings, and claims which follow.

Summary of the Invention

This invention provides novel polypeptide chains
20 useful as either one or both subunits of dimeric
osteogenic proteins which, when implanted in a
mammalian body in association with a matrix, can induce
at the locus of the implant the full developmental
cascade of endochondral bone formation and bone marrow
25 differentiation.

A key to these developments was the elucidation of
amino acid sequence and structure data of native bovine
osteogenic protein. A protocol was developed which
results in retrieval of active, substantially pure
30 osteogenic protein from bovine bone having a half-

maximum bone forming activity of about 0.8 to 1.0 ng per mg of implant. The availability of the material enabled the inventors to elucidate key structural details of the protein necessary to achieve bone formation. Knowledge of the protein's amino acid sequence and other structural features enabled the identification and cloning of native genes in the human genome.

Consensus DNA sequences based on partial sequence data and observed homologies with regulatory proteins disclosed in the literature were used as probes for extracting genes encoding osteogenic protein from human genomic and cDNA libraries. One of the consensus sequences was used to isolate a previously unidentified gene which, when expressed, encoded a protein comprising a region capable of inducing endochondral bone formation when properly modified, incorporated in a suitable matrix, and implanted as disclosed herein. The gene, called "hOP1" or "OP-1", is described in greater detail in U.S. 660,162, filed 27-SEP-91 the disclosure of which is herein incorporated by reference.

Fragments of the hOP1 DNA sequence subsequently were used to probe a mouse embryo cDNA library in search of additional genes encoding osteogenic proteins. This process isolated a heretofore unidentified DNA sequence which encodes a polypeptide chain referred to herein as mOP1 protein. Mouse OP1 (mOP-1) protein shares significant amino acid sequence homology with human hOP1 protein, particularly in the region encoding the mature protein. Based on detailed structural and physical analyses of hOP1 protein and the high degree of amino acid sequence homology between

the hOP1 and mOP-1 proteins, homodimers of mOP1
proteins and heterodimers comprising mOP1 protein are
believed to be capable of inducing endochondral bone
formation, when the protein is dispersed in a suitable
05 matrix, and implanted as disclosed herein.

The sequence of what is believed to be the mature
form of the murine protein, designated herein mOP1-S,
is (residues 292-430 of Seq. ID No. 1). The amino acid
sequence of the full length protein, mOP1-PP (the
10 "prepro" form, see infra), and the cDNA sequence
encoding it are set forth in Seq. ID No. 1.

The invention provides recombinant dimeric
proteins, and osteogenic devices comprising these
proteins, wherein the subunits of the osteogenic dimers
15 comprise an amino acid sequence described by Seq. ID
No. 1, including allelic and biosynthetically mutated
variants thereof.

Mouse OP1 can be expressed from intact or truncated
cDNA or from synthetic DNAs in prokaryotic or
20 eucaryotic host cells, and then purified, cleaved,
refolded, dimerized, and implanted in experimental
animals. Currently preferred host cells include E.
coli, or mammalian cells, such as CHO, COS or BSC
cells. The osteogenic protein of the invention may
25 include forms having varying glycosylation patterns,
varying N-termini, a family of related proteins having
regions of amino acid sequence homology, and active
truncated or mutated forms of native or biosynthetic
protein, produced by expression of recombinant DNA in
host cells.
30

Thus, in view of this disclosure, skilled genetic engineers can isolate genes from cDNA or genomic libraries of various different species which encode appropriate amino acid sequences, or construct DNAs from oligonucleotides, and then can express them in various types of host cells, including both prokaryotes and eukaryotes, to produce large quantities of active proteins capable of inducing bone formation in mammals including humans.

In view of this disclosure, and using standard immunology techniques well known in the art, those skilled in the art also may raise polyclonal or monoclonal antibodies against all or part of the polypeptide chains described herein. Useful protocols for antibody production may be found, for example, in Molecular Cloning-A Laboratory Manual (Sambrook et al., eds.) Cold Spring Harbor Press 2nd ed. 1989). See Book 3, Section 18.

The osteogenic proteins are useful in clinical applications in conjunction with a suitable delivery or support system (matrix). The matrix is made up of particles of porous materials. The pores must be of a dimension to permit progenitor cell migration and subsequent differentiation and proliferation. The particle size should be within the range of 70 - 850 mm, preferably 150mm - 420mm. It may be fabricated by close packing particulate material into a shape spanning the bone defect, or by otherwise structuring as desired a material that is biocompatible (non-inflammatory) and, biodegradable in vivo to serve as a "temporary scaffold" and substratum for recruitment of migratory progenitor cells, and as a base for their subsequent anchoring and proliferation. Currently

preferred carriers include particulate, demineralized, guanidine extracted, species-specific (allogenic) bone, and specially treated particulate, protein extracted, demineralized, xenogenic bone. Optionally, such
05 xenogenic bone powder matrices also may be treated with proteases such as trypsin and/or fibril modifying agents to increase the intraparticle intrusion volume and surface area. Useful agents include solvents such as dichloromethane, trichloroacetic acid, acetonitrile
10 and acids such as trifluoroacetic acid and hydrogen fluoride. Alternatively, the matrix may be treated with a hot aqueous medium having a temperature within the range of about 37°C to 75°C, including heated acidic aqueous medium. Other potentially useful matrix
15 materials comprise collagen, homopolymers and copolymers of glycolic acid and lactic acid, hydroxyapatite, tricalcium phosphate and other calcium phosphates.

The osteogenic proteins and implantable osteogenic
20 devices enabled and disclosed herein will permit the physician to obtain optimal predictable bone formation to correct, for example, acquired and congenital craniofacial and other skeletal or dental anomalies (Glowacki et al. (1981) Lancet 1: 959-963). The
25 devices may be used to induce local endochondral bone formation in non-union fractures as demonstrated in animal tests, and in other clinical applications including dental and periodontal applications where bone formation is required. Another potential clinical
30 application is in cartilage repair, for example, in the treatment of osteoarthritis.

Brief Description of the Drawing

The foregoing and other objects of this invention, the various features thereof, as well as the invention itself, may be more fully understood from the following 05 description, when read together with the accompanying drawings, in which:

FIGURE 1 compares the amino acid sequences of the mature hOP1 and mOP1 polypeptide chains: OP1-18 and mOP1-S.

10 Description

Purification protocols first were developed which enabled isolation of the osteogenic protein present in crude protein extracts from mammalian bone. (See PCT US 89/01453, and U.S. Serial No. 179,406 filed April 8, 15 1988, now U.S. Patent No. 4,968,950). The development of the procedure, coupled with the availability of fresh calf bone, enabled isolation of substantially pure bovine osteogenic protein (bOP). bOP was characterized significantly; its ability to induce 20 cartilage and ultimately endochondral bone growth in cat, rabbit, and rat were demonstrated and studied; it was shown to be able to induce the full developmental cascade of bone formation previously ascribed to unknown protein or proteins in heterogeneous bone 25 extracts. This dose dependent and highly specific activity was present whether or not the protein was glycosylated (see (1990) J. Biol. Chem. 265: 13198- 13205). Sequence data obtained from the bovine materials suggested probe designs which were used to 30 isolate human genes. The OP human counterpart proteins have now been expressed and extensively characterized.

These discoveries enabled preparation of DNAs encoding totally novel, non-native protein constructs which individually as homodimers and combined with other species as heterodimers are capable of producing true endochondral bone (see PCT WO 89/09788, published 19-OCT-89 and US Serial No. 315,342, filed 23-FEB-89, now U.S. Patent No. 5,011,691.) They also permitted expression of the natural material, truncated forms, muteins, analogs, fusion proteins, and various other variants and constructs, from cDNAs and genomic DNAs retrieved from natural sources or from synthetic DNA produced using the techniques disclosed herein and using automated, commercially available equipment. The DNAs may be expressed using well established molecular biology and recombinant DNA techniques in prokaryotic or eucaryotic host cells, and may be oxidized and refolded in vitro if necessary, to produce biologically active protein.

One of the DNA sequences isolated from human genomic and cDNA libraries encoded a previously unidentified gene, referred to herein as hOP1. The protein encoded by the isolated DNA was identified originally by amino acid homology with proteins in the TGF- β family. Consensus splice signals were found where amino acid homologies ended, designating exon-intron boundaries. Three exons were combined to obtain a functional TGF- β like domain containing seven cysteines. (See, for example, U.S. Patent No. 5,011,691 or Ozkaynak, E. et al., (1990) EMBO. 9: pp. 2085-2093). The DNA also is referred to in related applications as "OP1 and "OP-1".

In its native form, hOP1 expression yields an immature translation product ("hOP1-PP", where "PP" refers to "prepro form") of about 400 amino acids that subsequently is processed to yield a mature sequence of 05 139 amino acids ("OP1-18"). The active region (functional domain) of the protein comprises the C-terminal 97 amino acids of the hOP1 sequence, "OPS", which includes a conserved six cysteine skeleton. A longer active sequence is OP7, comprising the C-10 terminal 102 amino acids, and which includes a conserved seven cysteine skeleton.

The full length cDNA sequence for hOP1, and its encoded "prepro" form hOP1-PP, which includes an N-terminal signal peptide sequence, are disclosed in 15 Seq. ID No. 3 (residues 1-431). The mature form of hOP1 protein expressed in mammalian cells, designated herein OP1-18, is indicated by residues 293-431 of Seq. ID No. 3.

CDNA sequences encoding the "prepro" form, of the 20 protein and the mature form, as well as various truncated forms of the gene, and fused genes, have been expressed in E. coli (see, for example, U.S. Serial No. 422, 699) and numerous mammalian cells (See, for example, PCT WO 91/05802, published 2-MAY-91, and all 25 have been shown to have osteogenic activity when implanted in a mammal in association with a suitable matrix.

Given the foregoing amino acid and DNA sequence information, various nucleic acids (RNAs and DNAs) can 30 be constructed which encode at least the active region of an OP1 protein (e.g., OPS or OP7, amino acid residues 335-431 or 330-431, respectively, of Seq. ID

No. 3) and various analogs thereof, as well as fusion proteins, truncated forms of the mature proteins, and similar constructs. Moreover, DNA hybridization probes can be constructed from fragments of the hOP1 DNA or 05 designed de novo based on the hOP1 DNA or amino acid sequence. These probes then can be used to screen different genomic and cDNA libraries to identify additional osteogenic proteins.

The DNAs can be produced by those skilled in the 10 art using well known DNA manipulation techniques involving genomic and cDNA isolation, construction of synthetic DNA from synthesized oligonucleotides, and cassette mutagenesis techniques. 15-100mer oligonucleotides may be synthesized on a Biosearch DNA 15 Model 8600 Synthesizer, and purified by polyacrylamide gel electrophoresis (PAGE) in Tris-Borate-EDTA buffer. The DNA may then be electroeluted from the gel. Overlapping oligomers may be phosphorylated by T4 polynucleotide kinase and ligated into larger blocks 20 which may also be purified by PAGE.

DNAs for use as hybridization probes may be labelled (e.g., as with a radioisotope, by nick translation) and used to identify clones in a given library containing DNA to which the probe hybridizes, 25 following techniques well known in the art. The libraries may be obtained commercially or they may be constructed de novo using conventional molecular biology techniques. Further information on DNA library construction and hybridization techniques can be found 30 in numerous texts known to those skilled in the art. See, for example, F.M. Ausubel, ed., Current Protocols in Molecular Biology-Vol. 1, (1989). In particular,

see unit 5, "Construction of Recombinant DNA Libraries" and Unit 6, "Screening of Recombinant Libraries."

Appropriately identified clones then can be sequenced using any of a number of techniques well known in the art. A DNA fragment containing the sequence of interest then can be subcloned into an expression vector and transfected into an appropriate host cell for protein expression and further characterization. The host may be a procaryotic or eucaryotic cell since the former's inability to glycosylate protein will not destroy the protein's osteogenic activity. Useful host cells include E. coli, Saccharomyces, the insect/baculovirus cell system, myeloma cells, and various mammalian cells.

The vector additionally may encode various sequences to promote correct expression of the recombinant protein, including transcription promoter and termination sequences, enhancer sequences, preferred ribosome binding site sequences, preferred mRNA leader sequences, preferred signal sequences for protein secretion, and the like. The DNA sequence encoding the gene of interest also may be manipulated to remove potentially inhibiting sequences or to minimize unwanted secondary structure formation. The recombinant osteogenic protein also may be expressed as a fusion protein. After being translated, the protein may be purified from the cells themselves or recovered from the culture medium. All biologically active protein forms comprise dimeric species joined by disulfide bonds or otherwise associated, produced by oxidizing and refolding one or more of the various recombinant proteins within an appropriate eucaryotic cell or in vitro after expression of individual subunits. A detailed description of osteogenic protein

expressed from recombinant DNA in E. coli is disclosed in U.S. Serial No. 660,162, the disclosure of which has been incorporated by reference, supra. A detailed description of osteogenic protein expressed from recombinant DNA in numerous different mammalian cells is disclosed in PCT WO 91/05802.

Exemplification

In an effort to identify additional DNA sequences encoding osteogenic proteins, a hybridization probe specific to the C-terminus of the DNA of mature hOP1 was prepared using a StuI-EcoR1 digest fragment of hOP1 (base pairs 1034-1354 in Seq. ID No. 3), and labelled with ^{32}P by nick translation, as described in the art. The C-terminus of the protein encodes a key functional domain e.g., the "active region" for osteogenic activity. The C-terminus also is the region of the protein whose amino acid sequence shares specific amino acid sequence homology with particular proteins in the TGF- β super-family of regulatory proteins and which includes the conserved cysteine skeleton.

Approximately 7×10^5 phages of an oligo (dT) primed 17.5 days p.c. mouse embryo 5' stretch cDNA (gt10) library (Clontech, Inc., Palo Alto, CA) was screened with the labelled probe. The screen was performed using the following stringent hybridization conditions: 40% formamide, 5 x SSPE, 5 x Denhardt's solution, 0.1% SDS, at 37°C overnight, and washing in 0.1 x SSPE, 0.1% SDS, at 50°C.

Five recombinant phages were purified over three rounds of screening. Phage DNA was prepared from all five phages, subjected to an EcoR1 digest, subcloned

into the EcoRI site of common pUC-type plasmid modified to allow single strand sequencing, and sequenced using means well known in the art.

Two different DNA sequences were identified by this
05 procedure. One DNA, referred to herein as mOP2, is described in detail in copending USSN 599,543, filed 18-Oct-90. A second DNA, referred to herein as mOP1, is described below.

The cDNA and encoded amino acid sequence for the
10 full length mOP1 protein is depicted in Seq. ID No. 1. The full-length form of the protein is referred to as the prepro form of mOP-1 ("mOP1-PP"), and includes a signal peptide sequence at its N-terminus. The amino acid sequence Ser-Ala-Leu-Ala-Asp (amino acid residues
15 26-30 in Seq. ID No. 1) is believed to constitute the cleavage site for the removal of the signal peptide sequence, leaving an intermediate form of the protein, the "pro" form, to be secreted from the expressing cell. The amino acid sequence Arg-Ser-Ile-Arg-Ser
20 (amino acid residue nos. 288-292 in Seq. ID No. 1) is believed to constitute the cleavage site that produces the mature form of the protein, herein referred to as "mOP1-S" and described by amino acid residues 292-430 of Seq. ID No. 1. The region of the mOP1 amino acid
25 sequence corresponding to the conserved six cysteine skeleton is described by residues 334-430 of Seq. ID No. 1. The region corresponding to the conserved seven cystein skeleton is described by residues 329-430 of Seq. ID No. 1.

30 Figure 1 compares the amino acid sequence homology of the mature hOP1 and mOP1 proteins (OP1-18 and mOP1-S). Amino acid identity is indicated by three

dots (...). As can be seen in Figure 1, the mature form of mOP1, mOP1-S shows significant sequence homology with OP-1-18 (98%), differing at only three positions in this region. Like OP-1-18, mOP1-S has a 05 seven cysteine functional domain (residues 38-139 of Fig. 1). The prepro form of the mOP1 protein shares substantially less amino acid sequence homology with that of OP1-PP. The high degree of homology of the mature domains is not surprising as the amino acid 10 sequences of the mature forms of TGF- β -like proteins generally also have been found to be highly conserved across different animal species (e.g., compare Vgr and Vgl, two related genes from mouse and Xenopus, respectively, see U.S. Pat. No. 5,011,691). The high 15 degree of amino acid sequence homology exhibited between the mature forms of the two animal species of OP1 proteins identified suggests that the mOP-1 protein will purify essentially as the human OP1 protein does, or with only minor modifications of the protocols 20 disclosed for human OP1 protein. Similarly, purified mOP1-S is predicted to have an apparent molecular weight of about 36 kD as a glycosylated oxidized homodimer, and about 18 kD as a reduced single subunit, as determined by comparison with molecular weight 25 standards on an SDS-polyacrylamide electrophoresis gel. There appear to be three potential N glycosylation sites in the mature mOP1 protein. The unglycosylated homodimer (e.g., one expressed from E. coli) is predicted to have a molecular weight of about 27 kD.

A. General Consideration of Matrix Properties

The currently preferred carrier material is a xenogenic bone-derived particulate matrix treated as disclosed herein. This carrier may be replaced by either a biodegradable-synthetic or synthetic-inorganic matrix (e.g., hydroxylapatite (HAP), collagen, tricalcium phosphate or polylactic acid, polyglycolic acid and various copolymers thereof.)

Studies have shown that surface charge, particle size, the presence of mineral, and the methodology for combining matrix and osteogenic protein all play a role in achieving successful bone induction. Perturbation of the charge by chemical modification abolishes the inductive response. Particle size influences the quantitative response of new bone; particles between 75 μm and 420 μm elicit the maximum response. Contamination of the matrix with bone mineral will inhibit bone formation. Most importantly, the procedures used to formulate OP onto the matrix are extremely sensitive to the physical and chemical state of both the osteogenic protein and the matrix.

The sequential cellular reactions in the interface of the bone matrix/osteogenic protein implants are complex. The multistep cascade includes: binding of fibrin and fibronectin to implanted matrix, chemotaxis of cells, proliferation of fibroblasts, differentiation into chondroblasts, cartilage formation, vascular invasion, bone formation, remodeling, and bone marrow differentiation.

A successful carrier for osteogenic protein must perform several important functions. It must bind osteogenic protein and act as a slow release delivery system, accommodate each step of the cellular response

during bone development, and protect the osteogenic protein from nonspecific proteolysis. In addition, selected materials must be biocompatible in vivo and preferably biodegradable; the carrier must act as a
05 temporary scaffold until replaced completely by new bone. Polylactic acid (PLA), polyglycolic acid (PGA), and various combinations have different dissolution rates in vivo. In bones, the dissolution rates can vary according to whether the implant is placed in
10 cortical or trabecular bone.

Matrix geometry, particle size, the presence of surface charge, and the degree of both intra-and-inter-particle porosity are all important to successful matrix performance. It is preferred to shape the
15 matrix to the desired form of the new bone and to have dimensions which span non-union defects. Rat studies show that the new bone is formed essentially having the dimensions of the device implanted.

The matrix may comprise a shape-retaining
20 solid made of loosely adhered particulate material, e.g., with collagen. It may also comprise a molded, porous solid, or simply an aggregation of close-packed particles held in place by surrounding tissue.

Masticated muscle or other tissue may also be used.
25 Large allogenic bone implants can act as a carrier for the matrix if their marrow cavities are cleaned and packed with particle and the dispersed osteogenic protein.

The preferred matrix material, prepared from
30 xenogenic bone and treated as disclosed herein, produces an implantable material useful in a variety of clinical settings. In addition to its use as a matrix

for bone formation in various orthopedic, periodontal, and reconstructive procedures, the matrix also may be used as a sustained release carrier, or as a collagenous coating for implants. The matrix may be
05 shaped as desired in anticipation of surgery or shaped by the physician or technician during surgery. Thus, the material may be used for topical, subcutaneous, intraperitoneal, or intramuscular implants; it may be shaped to span a nonunion fracture or to fill a bone
10 defect. In bone formation or conduction procedures, the material is slowly absorbed by the body and is replaced by bone in the shape of or very nearly the shape of the implant.

Various growth factors, hormones, enzymes,
15 therapeutic compositions, antibiotics, and other body treating agents also may be absorbed onto the carrier material and will be released over time when implanted as the matrix material is slowly absorbed. Thus, various known growth factors such as EGF, PDGF, IGF,
20 FGF, TGF- α , and TGF- β may be released in vivo. The material can be used to release chemotherapeutic agents, insulin, enzymes, or enzyme inhibitors.

B. Bone-Derived Matrices

1. Preparation of Demineralized Bone

25 Demineralized bone matrix, preferably bovine bone matrix, is prepared by previously published procedures (Sampath and Reddi (1983) Proc. Natl. Acad. Sci. USA 80:6591-6595). Bovine diaphyseal bones (age 1-10 days) are obtained from a local slaughterhouse and
30 used fresh. The bones are stripped of muscle and fat,

cleaned of periosteum, demarrowed by pressure with cold water, dipped in cold absolute ethanol, and stored at -20°C. They are then dried and fragmented by crushing and pulverized in a large mill. Care is taken to
05 prevent heating by using liquid nitrogen. The pulverized bone is milled to a particle size in the range of 70-850 μm , preferably 150-420 μm , and is defatted by two washes of approximately two hours duration with three volumes of chloroform and methanol
10 (3:1). The particulate bone is then washed with one volume of absolute ethanol and dried over one volume of anhydrous ether yielding defatted bone powder. The defatted bone powder is then demineralized by four successive treatments with 10 volumes of 0.5 N HCl at
15 4°C for 40 min. Finally, neutralizing washes are done on the demineralized bone powder with a large volume of water.

2. Guanidine Extraction

Demineralized bone matrix thus prepared is
20 extracted with 5 volumes of 4 M guanidine-HCl, 50mM Tris-HCl, pH 7.0 for 16 hr. at 4°C. The suspension is filtered. The insoluble material is collected and used to fabricate the matrix. The material is mostly collagenous in nature. It is devoid of osteogenic or
25 chondrogenic activity.

3. Matrix Treatments

The major component of all bone matrices is Type-I collagen. In addition to collagen, demineralized bone extracted as disclosed above
30 includes non-collagenous proteins which may account for 5% of its mass. In a xenogenic matrix, these

noncollagenous components may present themselves as potent antigens, and may constitute immunogenic and/or inhibitory components. These components also may inhibit osteogenesis in allogenic implants by

05 interfering with the developmental cascade of bone differentiation. It has been discovered that treatment of the matrix particles with a collagen fibril-modifying agent extracts potentially unwanted components from the matrix, and alters the surface

10 structure of the matrix material. Useful agents include acids, organic solvents or heated aqueous media. Various treatments are described below. A detailed physical analysis of the effect these fibril-modifying agents have on demineralized, quanidine-

15 extracted bone collagen particles is disclosed in copending U.S. Patent Application Serial No. 483,913, filed February 22, 1990.

After contact with the fibril-modifying agent, the treated matrix is washed to remove any extracted

20 components, following a form of the procedure set forth below:

1. Suspend in TBS (Tris-buffered saline) 1g/200 ml and stir at 4°C for 2 hrs; or in 6 M urea, 50 mM Tris-HCl, 500 mM NaCl, pH 7.0 (UTBS) or water and

25 stir at room temperature (RT) for 30 minutes (sufficient time to neutralize the pH);

2. Centrifuge and repeat wash step; and

3. Centrifuge; discard supernatant; water wash residue; and then lyophilize.

30 3.1 Acid Treatments

1. Trifluoroacetic acid.

Trifluoroacetic acid is a strong non-oxidizing acid that is a known swelling agent for proteins, and which modifies collagen fibrils.

05 Bovine bone residue prepared as described above is sieved, and particles of the appropriate size are collected. These particles are extracted with various percentages (1.0% to 100%) of trifluoroacetic acid and water (v/v) at 0°C or room temperature for 1-2
10 hours with constant stirring. The treated matrix is filtered, lyophilized, or washed with water/salt and then lyophilized.

2. Hydrogen Fluoride.

Like trifluoroacetic acid, hydrogen fluoride
15 is a strong acid and swelling agent, and also is capable of altering intraparticle surface structure. Hydrogen fluoride is also a known deglycosylating agent. As such, HF may function to increase the osteogenic activity of these matrices by removing the
20 antigenic carbohydrate content of any glycoproteins still associated with the matrix after guanidine extraction.

Bovine bone residue prepared as described above is sieved, and particles of the appropriate size are
25 collected. The sample is dried in vacuo over P₂O₅, transferred to the reaction vessel and exposed to anhydrous hydrogen fluoride (10-20 ml/g of matrix) by distillation onto the sample at -70°C. The vessel is allowed to warm to 0°C and the reaction mixture is

stirred at this temperature for 120 minutes. After evaporation of the hydrogen fluoride in vacuo, the residue is dried thoroughly in vacuo over KOH pellets to remove any remaining traces of acid. Extent of
05 deglycosylation can be determined from carbohydrate analysis of matrix samples taken before and after treatment with hydrogen fluoride, after washing the samples appropriately to remove non-covalently bound carbohydrates. SDS-extracted protein from HF-treated
10 material is negative for carbohydrate as determined by Con A blotting.

The deglycosylated bone matrix is next washed twice in TBS (Tris-buffered saline) or UTBS, water-washed, and then lyophilized.

15 Other acid treatments are envisioned in addition to HF and TFA. TFA is a currently preferred acidifying reagent in these treatments because of its volatility. However, it is understood that other, potentially less caustic acids may be used, such as
20 acetic or formic acid.

3.2 Solvent Treatment

1. Dichloromethane.

Dichloromethane (DCM) is an organic solvent capable of denaturing proteins without affecting their
25 primary structure. This swelling agent is a common reagent in automated peptide synthesis, and is used in washing steps to remove components.

Bovine bone residue, prepared as described above, is sieved, and particles of the appropriate size

are incubated in 100% DCM or, preferably, 99.9% DCM/0.1% TFA. The matrix is incubated with the swelling agent for one or two hours at 0°C or at room temperature. Alternatively, the matrix is treated with
05 the agent at least three times with short washes (20 minutes each) with no incubation.

2. Acetonitrile.

Acetonitrile (ACN) is an organic solvent, capable of denaturing proteins without affecting their
10 primary structure. It is a common reagent used in high-performance liquid chromatography, and is used to elute proteins from silica-based columns by perturbing hydrophobic interactions.

Bovine bone residue particles of the
15 appropriate size, prepared as described above, are treated with 100% ACN (1.0 g/30 ml) or, preferably, 99.9% ACN/0.1% TFA at room temperature for 1-2 hours with constant stirring. The treated matrix is then water-washed, or washed with urea buffer, or 4 M NaCl
20 and lyophilized. Alternatively, the ACN or ACN/TFA treated matrix may be lyophilized without wash.

3. Isopropanol.

Isopropanol is also an organic solvent capable of denaturing proteins without affecting their primary
25 structure. It is a common reagent used to elute proteins from silica HPLC columns.

Bovine bone residue particles of the appropriate size prepared as described above are treated with 100% isopropanol (1.0 g/30 ml) or,

preferably, in the presence of 0.1% TFA, at room temperature for 1-2 hours with constant stirring. The matrix is then water-washed or washed with urea buffer or 4 M NaCl before being lyophilized.

05 4. Chloroform

Chloroform also may be used to increase surface area of bone matrix like the reagents set forth above, either alone or acidified.

Treatment as set forth above is effective to
10 assure that the material is free of pathogens prior to
implantation.

3.3 Heat Treatment

The currently most preferred agent is a heated aqueous fibril-modifying medium such as water, to
15 increase the matrix particle surface area and porosity. The currently most preferred aqueous medium is an acidic aqueous medium having a pH of less than about 4.5, e.g., within the range of pH 2 - pH 4. which may help to "swell" the collagen before heating. 0.1%
20 acetic acid, which has a pH of about 3, currently is preferred. 0.1 M acetic acid also may be used.

Various amounts of delipidated, demineralized guanidine-extracted bone collagen are heated in the aqueous medium (1g matrix/30ml aqueous medium) under
25 constant stirring in a water jacketed glass flask, and maintained at a given temperature for a predetermined period of time. Preferred treatment times are about one hour, although exposure times of between about 0.5 to two hours appear acceptable. The temperature

employed is held constant at a temperature within the range of about 37°C to 75°C. The currently preferred heat treatment temperature is within the range of 45°C to 60°C.

05 After the heat treatment, the matrix is filtered, washed, lyophilized and used for implant. Where an acidic aqueous medium is used, the matrix also is preferably neutralized prior to washing and lyophilization. A currently preferred neutralization
10 buffer is a 200mM sodium phosphate buffer, pH 7.0. To neutralize the matrix, the matrix preferably first is allowed to cool following thermal treatment, the acidic aqueous medium (e.g., 0.1% acetic acid) then is removed and replaced with the neutralization buffer and the
15 matrix agitated for about 30 minutes. The neutralization buffer then may be removed and the matrix washed and lyophilized (see infra).

The matrix also may be treated to remove contaminating heavy metals, such as by exposing the
20 matrix to a metal ion chelator. For example, following thermal treatment with 0.1% acetic acid, the matrix may be neutralized in a neutralization buffer containing EDTA (sodium ethylenediaminetetraacetic acid), e.g., 200 mM sodium phosphate, 5mM EDTA, pH 7.0. 5 mM EDTA
25 provides about a 100-fold molar excess of chelator to residual heavy metals present in the most contaminated matrix tested to date. Subsequent washing of the matrix following neutralization appears to remove the bulk of the EDTA. EDTA treatment of matrix particles
30 reduces the residual heavy metal content of all metals tested (Sb, As, Be, Cd, Cr, Cu, Co, Pb, Hg, Ni, Se, Ag, Zn, Tl) to less than about 1 ppm. Bioassays with EDTA-

treated matrices indicate that treatment with the metal ion chelator does not inhibit bone inducing activity.

The collagen matrix materials preferably take the form of a fine powder, insoluble in water, comprising nonadherent particles. It may be used simply by packing into the volume where new bone growth or sustained release is desired, held in place by surrounding tissue. Alternatively, the powder may be encapsulated in, e.g., a gelatin or polylactic acid coating, which is adsorbed readily by the body. The powder may be shaped to a volume of given dimensions and held in that shape by interadhering the particles using, for example, soluble, species-biocompatible collagen. The material may also be produced in sheet, rod, bead, or other macroscopic shapes.

FABRICATION OF OSTEOGENIC DEVICE

The naturally sourced and recombinant protein as set forth above, and other constructs, can be combined and dispersed in a suitable matrix preparation using any of the methods described below. In general, 50-100 mg of active protein is combined with the inactive carrier matrix (e.g., 25 mg for rat bioassays). Greater amounts may be used for large implants.

1. Ethanol Precipitation

Matrix is added to osteogenic protein dissolved in guanidine-HCl. Samples are vortexed and incubated at a low temperature (e.g., 4°C). Samples are then further vortexed. Cold absolute ethanol (5 volumes) is added to the mixture which is then stirred

and incubated, preferably for 30 minutes at -20°C. After centrifugation (microfuge, high speed) the supernatant is discarded. The reconstituted matrix is washed twice with cold concentrated ethanol in water
05 (85% EtOH) and then lyophilized.

2. Acetonitrile Trifluoroacetic Acid Lyophilization

In this procedure, osteogenic protein in an acetonitrile trifluroacetic acid (ACN/TFA) solution is
10 added to the carrier material. Samples are vigorously vortexed many times and then lyophilized. This method is currently preferred, and has been tested with osteogenic protein at varying concentrations and different levels of purity.

15 3. Urea Lyophilization

For those osteogenic proteins that are prepared in urea buffer, the protein is mixed with the matrix material, vortexed many times, and then
20 lyophilized. The lyophilized material may be used "as is" for implants.

4. Buffered Saline Lyophilization

CPI preparations in physiological saline may also be vortexed with the matrix and lyophilized to produce osteogenically active material.

25 These procedures also can be used to adsorb other active therapeutic drugs, hormones, and various bioactive species to the matrix for sustained release purposes.

BIOASSAY

The functioning of the various proteins and devices of this invention can be evaluated with an in vivo bioassay. Studies in rats show the osteogenic effect in an appropriate matrix to be dependent on the dose of osteogenic protein dispersed in the matrix. No activity is observed if the matrix is implanted alone. In vivo bioassays performed in the rat model also have shown that demineralized, guanidine-extracted xenogenic bone matrix materials of the type described in the literature are ineffective as a carrier, fail to induce bone, and produce an inflammatory and immunological response when implanted unless treated as disclosed above. In certain species (e.g., monkey) allogenic matrix materials also apparently are ineffective as carriers. The following sets forth various procedures for preparing osteogenic devices from the proteins and matrix materials prepared as set forth above, and for evaluating their osteogenic utility.

20 A. Rat Model

1. Implantation

The bioassay for bone induction as described by Sampath and Reddi ((1983) Proc. Natl. Acad. Sci. USA 80 6591-6595), herein incorporated by reference, may be used to monitor endochondral bone differentiation activity. This assay consists of implanting test samples in subcutaneous sites in recipient rats under ether anesthesia. Male Long-Evans rats, aged 28-32 days, were used. A vertical incision (1 cm) is made under sterile conditions in the skin over the thoracic

region, and a pocket is prepared by blunt dissection. Approximately 25 mg of the test sample is implanted deep into the pocket and the incision is closed with a metallic skin clip. The day of implantation is
05 designated as day one of the experiment. Implants were removed on day 12. The heterotopic site allows for the study of bone induction without the possible ambiguities resulting from the use of orthotropic sites. As disclosed herein, both allogenic (rat bone
10 matrix) and xenogenic (bovine bone matrix) implants were assayed.

2. Cellular Events

Successful implants exhibit a controlled progression through the stages of protein-induced
15 endochondral bone development, including: (1) transient infiltration by polymorphonuclear leukocytes on day one; (2) mesenchymal cell migration and proliferation on days two and three; (3) chondrocyte appearance on days five and six; (4) cartilage matrix formation on
20 day seven; (5) cartilage calcification on day eight; (6) vascular invasion, appearance of osteoblasts, and formation of new bone on days nine and ten; (7) appearance of osteoblastic and bone remodeling and dissolution of the implanted matrix on days twelve to
25 eighteen; and (8) hematopoietic bone marrow differentiation in the ossicle on day twenty-one. The results show that the shape of the new bone conforms to the shape of the implanted matrix.

3. Histological Evaluation

30 Histological sectioning and staining is preferred to determine the extent of osteogenesis in

the implants. Implants are fixed in Bouins Solution, embedded in paraffin, and cut into 6-8 μm sections. Staining with toluidine blue or hemotoxylin/eosin demonstrates clearly the ultimate development of
05 endochondral bone. Twelve day implants are usually sufficient to determine whether the implants contain newly induced bone.

4. Biological Markers

Alkaline phosphatase activity may be used as a
10 marker for osteogenesis. The enzyme activity may be determined spectrophotometrically after homogenization of the implant. The activity peaks at 9-10 days in vivo and thereafter slowly declines. Implants showing no bone development by histology have little or no
15 alkaline phosphatase activity under these assay conditions. The assay is useful for quantitation and obtaining an estimate of bone formation quickly after the implants are removed from the rat. Alternatively, the amount of bone formation can be determined by
20 measuring the calcium content of the implant.

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all
25 respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be
30 embraced therein.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

05 OZKAYNAK, ENGIN
OPPERMANN, HERMANN
KUBERASAMPATH, THANGAVEL
RUEGER, DAVID C.

(ii) TITLE OF INVENTION: OSTEOGENIC DEVICES

(iii) NUMBER OF SEQUENCES: 4

10 (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: TESTA, HURWITZ & THIBEAULT
(B) STREET: 53 STATE STREET
(C) CITY: BOSTON
(D) STATE: MASSACHUSETTS
15 (E) COUNTRY: U.S.A.
(F) ZIP: 02109

(v) COMPUTER READABLE FORM:

10 (A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patent In Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

25 (A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: PITCHER, EDMUND R.
(B) REGISTRATION NUMBER: 27,829
(C) REFERENCE/DOCKET NUMBER: CRP-001PC5

30 (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 617/248-7000
(B) TELEFAX: 617/248-7100

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 1873 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: MURIDAE
(F) TISSUE TYPE: EMBRYO

05 (ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 104..1393
(D) OTHER INFORMATION: /function= "OSTEOGENIC PROTEIN"
/product= "mOP1-PP"
/note= "mOP1 (CDNA)"

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CTGCAGCAAG	TGACCTCGGG	TCGTGGACCG	CTGCCCTGCC	CCCTCCGCTG	CCACCTGGGG	60
CGGCGCGGGC	CCGGTGCCCC	GGATCGCGCG	TAGAGCCGGC	GCG ATG CAC GTG CGC	Met His Val Arg	115
15 TCG CTG CGC GCT GCG GCG	CCA CAC AGC TTC GTG GCG CTC TGG GCG CCT	Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala Pro	5 10 15 20	163		
CTG TTC TTG CTG CGC TCC GCC CTG GCC GAT TTC AGC CTG GAC AAC GAG	Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn Glu	20 25 30 35	211			
GAG ATG CAG CGG GAG ATC CTG TCC ATC TTA GGG TTG CCC CAT CGC CCG	Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser Gln Glu Arg Arg	40 45 50	259			
25 Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu Pro His Arg Pro	55 60 65	307				
CGC CCG CAC CTC CAG GGA AAG CAT AAT TCG GCG CCC ATG TTC ATG TTG	Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro Met Phe Met Leu	70 75 80	355			
30 GAC CTG TAC AAC GCC ATG GCG GTG GAG GAG AGC GGG CCG GAC GGA CAG	Asp Leu Tyr Asn Ala Met Ala Val Glu Ser Gly Pro Asp Gly Gln	85 90 95 100	403			
GGC TTC TCC TAC CCC TAC AAG GCC GTC TTC AGT ACC CAG GGC CCC CCT	Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gln Gly Pro Pro	35 105 110 115	451			
TTA GCC AGC CTG CAG GAC AGC CAT TTC CTC ACT GAC GCC GAC ATG GTC	Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr Asp Ala Asp Met Val	120 125 130	499			
ATG AGC TTC GTC AAC CTA GTG GAA CAT GAC AAA GAA TTC TTC CAC CCT			547			

	Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu Phe Phe His Pro		
	135 140 145		
05	CGA TAC CAC CAT CGG GAG TTC CGG TTT GAT CTT TCC AAG ATC CCC GAG Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser Lys Ile Pro Glu 150 155 160		595
	GGC GAA GCG GTG ACC GCA GCC GAA TTC AGG ATC TAT AAG GAC TAC ATC Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys Asp Tyr Ile 165 170 175 180		643
10	CGG GAG CGA TTT GAC AAC GAG ACC TTC CAG ATC ACA GTC TAT CAG TGG Arg Glu Arg Phe Asp Asn Glu Thr Phe Gln Ile Thr Val Tyr Gln Trp 185 190 195		691
	CTC CAG GAG CAC TCA GGC AGG GAG TCG GAC CTC TTC TTG CTG GAC AGC Leu Gln Glu His Ser Gly Arg Glu Ser Asp Leu Phe Leu Leu Asp Ser 200 205 210		739
15	CGC ACC ATC TGG GCT TCT GAG GAG GGC TGG TTG GTG TTT GAT ATC ACA Arg Thr Ile Trp Ala Ser Glu Glu Gly Trp Leu Val Phe Asp Ile Thr 215 220 225		787
	GCC ACC AGC AAC CAC TGG GTG GTC AAC CCT CGG CAC AAC CTG GGC TTA Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His Asn Leu Gly Leu 230 235 240		835
20	CAG CTC TCT GTG GAG ACC CTG GAT GGG CAG AGC ATC AAC CCC AAG TTG Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser Ile Asn Pro Lys Leu 245 250 255 260		883
25	GCA GGC CTG ATT GGA CGG CAT GGA CCC CAG AAC AAG CAA CCC TTC ATG Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn Lys Gln Pro Phe Met 265 270 275		931
	GTG GCC TTC TTC AAG GCC ACG GAA GTC CAT CTC CGT AGT ATC CGG TCC Val Ala Phe Phe Lys Ala Thr Glu Val His Leu Arg Ser Ile Arg Ser 280 285 290		979
30	ACG GGG GGC AAG CAG CGC AGC CAG AAT CGC TCC AAG ACG CCA AAG AAC Thr Gly Lys Gln Arg Ser Gln Asn Arg Ser Lys Thr Pro Lys Asn 295 300 305		1027
	CAA GAG GCC CTG AGG ATG GCC AGT GTG GCA GAA AAC AGC AGC AGT GAC Gln Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn Ser Ser Ser Asp 310 315 320		1075
35	CAG AGG CAG GCC TGC AAG AAA CAT GAG CTG TAC GTC AGC TTC CGA GAC Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp 325 330 335 340		1123
40	CTT GGC TGG CAG GAC TGG ATC ATT GCA CCT GAA GGC TAT GCT GCC TAC Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala Tyr		1171

	345	350	355	
	TAC TGT GAG GGA GAG TGC GCC TTC CCT CTG AAC TCC TAC ATG AAC GCC Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn Ala 360			1219
05	ACC AAC CAC GCC ATC GTC CAG ACA CTG GTT CAC TTC ATC AAC CCA GAC Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe Ile Asn Pro Asp 375	380	385	1267
10	ACA GTA CCC AAG CCC TGC TGT GCG CCC ACC CAG CTC AAC GCC ATC TCT Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala Ile Ser 390	395	400	1315
	GTC CTC TAC TTC GAC GAC AGC TCT AAT GTC GAC CTG AAG AAG TAC AGA Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Asp Leu Lys Lys Tyr Arg 405	410	415	1363
15	AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCTTCC TGAGACCCCTG Asn Met Val Val Arg Ala Cys Gly Cys His 425	430		1413
	ACCTTTGCCGG GGCCACACCT TTCCAAATCT TCGATGTCTC ACCATCTAAG TCTCTCACTG			1473
	CCCACCTTGG CGAGGAGAAC AGACCAAACCT CTCCTGAGCC TTCCCTCACC TCCCAACCGG			1533
	AAGCATGTAA GGGTTCCAGA AACCTGAGCG TGCAGCAGCT GATGAGGCC CTTTCCTTCT			1593
20	GGCACGTGAC GGACAAGATC CTACCAGCTA CCACAGAAA CGCCTAAGAG CAGGAAAAAT			1653
	GTCTGCCAGG AAAGTGTCCA GTGTCCACAT GGCCCCCTGGC GCTCTGAGTC TTTGAGGAGT			1713
	AATCGCAAGC CTCGTTCAAGC TGCAGCAGAA GGAAGGGCTT AGCCAGGGTG GGCGCTGGCG			1773
	TCTGTGTTGA AGGGAAACCA AGCAGAAGCC ACTGTAATGA TATGTCACAA TAAAACCCAT			1833
	GAATGAAAAA AAAAAAAAAA AAAAAAAAAA AAAAGAATTG			1873

25 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 430 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

(ix) FEATURE:

(D) OTHER INFORMATION: /product= "mOP1-PP"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala
1 5 10 15

Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser
20 25 30

05 Leu Asp Asn Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser
35 40 45

Gln Glu Arg Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu
50 55 60

10 Pro His Arg Pro Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro
65 70 75 80

Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Ser Gly
85 90 95

Pro Asp Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr
100 105 110

15 Gln Gly Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr Asp
115 120 125

Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu
130 135 140

20 Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser
145 150 155 160

Lys Ile Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr
165 170 175

Lys Asp Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Gln Ile Thr
180 185 190

25 Val Tyr Gln Trp Leu Gln Glu His Ser Gly Arg Glu Ser Asp Leu Phe
195 200 205

Leu Leu Asp Ser Arg Thr Ile Trp Ala Ser Glu Glu Gly Trp Leu Val
210 215 220

30 Phe Asp Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His
225 230 235 240

Asn Leu Gly Leu Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser Ile
245 250 255

Asn Pro Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn Lys
260 265 270

35 Gln Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Leu Arg
275 280 285

Ser Ile Arg Ser Thr Gly Gly Lys Gln Arg Ser Gln Asn Arg Ser Lys
290 295 300

Thr Pro Lys Asn Gln Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn
305 310 315 320

05 Ser Ser Ser Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr Val
325 330 335

Ser Phe Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly
340 345 350

Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser
10 355 360 365

Tyr Met Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe
370 375 380

Ile Asn Pro Asp Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu
385 390 395 400

15 Asn Ala Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Asp Leu
405 410 415

Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His
420 425 430

(2) INFORMATION FOR SEQ ID NO:3:

- 20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1822 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- 25 (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
(A) ORGANISM: HOMO SAPIENS
(F) TISSUE TYPE: HIPPOCAMPUS
- 30 (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 49..1341
(C) IDENTIFICATION METHOD: experimental
(D) OTHER INFORMATION: /function= "OSTEOGENIC PROTEIN"
35 /product= "hOP1-PP"
/evidence= EXPERIMENTAL

/standard_name= "hOP1"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

	GGTGCAGGCC CGGAGCCCGG AGCCCCGGTA GCGCGTAGAG CCGGGCGG ATG CAC GTG	57
05	Met His Val	1
	CGC TCA CTG CGA GCT GCG GCG CCG CAC AGC TTC GTG GCG CTC TGG GCA	105
	Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala	
	5 10 15	
10	CCC CTG TTC CTG CTG CGC TCC GCC CTG GCC GAC TTC AGC CTG GAC AAC	153
	Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn	
	20 25 30 35	
	GAG GTG CAC TCG AGC TTC ATC CAC CGG CGC CTC CGC AGC CAG GAG CGG	201
	Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser Gln Glu Arg	
	40 45 50	
15	CGG GAG ATG CAG CGC GAG ATC CTC TCC ATT TTG GGC TTG CCC CAC CGC	249
	Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu Pro His Arg	
	55 60 65	
	CCG CGC CCG CAC CTC CAG GGC AAG CAC AAC TCG GCA CCC ATG TTC ATG	297
	Pro Arg Pro His Leu Gln Lys His Asn Ser Ala Pro Met Phe Met	
20	70 75 80	
	CTG GAC CTG TAC AAC GCC ATG GCG GTG GAG GAG GGC GGG CCC GGC	345
	Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly Pro Gly	
	85 90 95	
25	GGC CAG GGC TTC TCC TAC CCC TAC AAG GCC GTC TTC AGT ACC CAG GGC	393
	Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gln Gly	
	100 105 110 115	
	CCC CCT CTG GCC AGC CTG CAA GAT AGC CAT TTC CTC ACC GAC GCC GAC	441
	Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr Asp Ala Asp	
	120 125 130	
30	ATG GTC ATG AGC TTC GTC AAC CTC GTG GAA CAT GAC AAG GAA TTC TTC	489
	Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu Phe Phe	
	135 140 145	
	CAC CCA CGC TAC CAC CAT CGA GAG TTC CCG TTT GAT CTT TCC AAG ATC	537
	His Pro Arg Tyr His Arg Glu Phe Arg Phe Asp Leu Ser Lys Ile	
35	150 155 160	
	CCA GAA GGG GAA GCT GTC ACG GCA GCC GAA TTC CCG ATC TAC AAG GAC	585
	Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys Asp	
	165 170 175	
	TAC ATC CGG GAA CGC TTC GAC AAT GAG ACG TTC CGG ATC AGC GTT TAT	633

	Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg Ile Ser Val Tyr			
	180	185	190	195
05	CAG GTG CTC CAG GAG CAC TTG GGC AGG GAA TCG GAT CTC TTC CTG CTC Gln Val Leu Gln Glu His Leu Gly Arg Glu Ser Asp Leu Phe Leu Leu	200	205	210
				681
	GAC AGC CGT ACC CTC TGG GCC TCG GAG GAG GGC TGG CTG GTG TTT GAC Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu Val Phe Asp	215	220	225
10	ATC ACA GCC ACC AGC AAC CAC TGG GTG GTC AAT CCG CGG CAC AAC CTG Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His Asn Leu	230	235	240
				729
	GGC CTG CAG CTC TCG GTG GAG ACG CTG GAT GGG CAG AGC ATC AAC CCC Gly Leu Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser Ile Asn Pro	245	250	255
15	AAG TTG GCG GGC CTG ATT GGG CGG CAC GGG CCC CAG AAC AAG CAG CCC Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn Lys Gln Pro	260	265	270
				825
20	TTC ATG GTG GCT TTC TTC AAG GCC ACG GAG GTC CAC TTC CGC AGC ATC Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe Arg Ser Ile	280	285	290
				873
	CGG TCC ACG GGG AGC AAA CAG CGC AGC CAG AAC CGC TCC AAG ACG CCC Arg Ser Thr Gly Ser Lys Gln Arg Ser Gln Asn Arg Ser Lys Thr Pro	295	300	305
25	AAG AAC CAG GAA GCC CTG CGG ATG GCC AAC GTG GCA GAG AAC AGC AGC Lys Asn Gln Glu Ala Leu Arg Met Ala Asn Val Ala Glu Asn Ser Ser	310	315	320
				969
	AGC GAC CAG AGG CAG GCC TGT AAG AAG CAC GAG CTG TAT GTC AGC TTC Ser Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe	325	330	335
30	CGA GAC CTG GGC TGG CAG GAC TGG ATC ATC GCG CCT GAA GGC TAC GCC Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala	340	345	350
				1017
	350	355		
	GCC TAC TAC TGT GAG GGG GAG TGT GCC TTC CCT CTG AAC TCC TAC ATG Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met	360	365	370
				1065
35	AAC GCC ACC AAC CAC GCC ATC GTG CAG ACG CTG GTC CAC TTC ATC AAC Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe Ile Asn	375	380	385
				1161
40	CCG GAA ACG GTG CCC AAG CCC TGC TGT GCG CCC ACG CAG CTC AAT GCC Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala	385		1209
				1257

	390	395	400	
	ATC TCC GTC CTC TAC TTC GAT GAC AGC TCC AAC GTC ATC CTG AAG AAA Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu Lys Lys 405	410	415	1305
05	TAC AGA AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCCTCC Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His 420	425	430	1351
	GAGAATTCAAG ACCCTTTGGG GCCAAGTTTT TCTGGATCCT CCATTGCTCG CCTTGGCCAG			1411
	GAACCAGCAG ACCAACTGCC TTTTGTGAGA CCTTCCCCTC CCTATCCCCA ACTTTAAAGG			1471
10	TGTGAGAGTA TTAGGAAACA TGAGCAGCAT ATGGCTTTG ATCAGTTTT CAGTGGCAGC ATCCAATGAA CAAGATCCTA CAAGCTGTGC AGGCAAAACC TAGCAGGAAA AAAAAACAAAC GCATAAAGAA AAATGGCCGG GCCAGGTCA TGGCTGGAA GTCTCAGCCA TGCACGGACT CGTTTCCAGA GGTAATTATG AGCGCCTACC AGCCAGGCCA CCCAGCCGTG GGAGGAAGGG GGCGTGGCAA GGGGTGGGCA CATTGGTGTC TGTGCGAAAG GAAAATTGAC CCGGAAGTTC			1531
				1591
				1651
				1711
				1771
15	CTGTAATAAA TGTACAATA AAACGAATGA ATGAAAAAAA AAAAAAAA A			1822

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 431 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

- (ix) FEATURE:
 - (D) OTHER INFORMATION: /Product="hOP1-PP"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

25	Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala 1 5 10 15
	Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser 20 25 30
30	Leu Asp Asn Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser 35 40 45
	Gln Glu Arg Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu 50 55 60

Pro His Arg Pro Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro
65 70 75 80

Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly
85 90 95

05 Gly Pro Gly Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser
100 105 110

Thr Gln Gly Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr
115 120 125

Asp Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys
10 130 135 140

Glu Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu
145 150 155 160

Ser Lys Ile Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile
165 170 175

15 Tyr Lys Asp Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg Ile
180 185 190

Ser Val Tyr Gln Val Leu Gln Glu His Leu Gly Arg Glu Ser Asp Leu
195 200 205

20 Phe Leu Leu Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu
210 215 220

Val Phe Asp Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg
225 230 235 240

His Asn Leu Gly Leu Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser
245 250 255

25 Ile Asn Pro Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn
260 265 270

Lys Gln Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe
275 280 285

30 Arg Ser Ile Arg Ser Thr Gly Ser Lys Gln Arg Ser Gln Asn Arg Ser
290 295 300

Lys Thr Pro Lys Asn Gln Glu Ala Leu Arg Met Ala Asn Val Ala Glu
305 310 315 320

Asn Ser Ser Ser Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr
325 330 335

35 Val Ser Phe Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu
340 345 350

Gly Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn
355 360 365

Ser Tyr Met Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His
370 375 380

05 Phe Ile Asn Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln
385 390 395 400

Leu Asn Ala Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile
405 410 415

10 Leu Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His
420 425 430

What is claimed is:

1. A polypeptide chain comprising an amino acid sequence described by residues 334-430 of Seq. ID No. 1.
- 5 2. The polypeptide chain of claim 1 comprising an amino acid sequence described by residues 329-430 of Seq. ID No. 1.
- 10 3. The polypeptide chain of claim 2 comprising an amino acid sequence described by residues 292-430 of Seq. ID No. 1.
4. The polypeptide chain of claim 3 comprising an amino acid sequence described by residues 1-430 of Seq. ID No. 1.
- 15 5. A polypeptide chain useful as a subunit of a dimeric osteogenic protein, said protein being capable of inducing endochondral bone formation when implanted in a mammal in association with a matrix;
20 said polypeptide chain comprising an amino acid sequence described by residues 334-430 of Seq. ID No. 1, including allelic variants thereof.
- 25 6. The polypeptide chain of claim 5 wherein said polypeptide chain comprises the amino acid sequence described by residues 292-430 of Seq. ID No. 1, including allelic variants thereof.:

7. The polypeptide chain of claim 1 or 5 produced by expression of recombinant DNA in a host cell.
8. The polypeptide chain of claim 7 wherein said host cell is a eucaryotic host cell.
05
9. The polypeptide chain of claim 8 wherein said eucaryotic host cell is a mammalian cell.
10. The polypeptide chain of claim 7 wherein said host cell is a procaryotic host cell.
11. The polypeptide chain of claim 10 wherein said procaryotic host cell is E.coli.
10
12. The polypeptide chain of claim 1 or 5 that is glycosylated.
13. A nucleic acid encoding the polypeptide chain of claim 1 or 5.
15
14. An osteogenic protein capable of inducing endochondral bone formation when implanted in a mammal in association with a matrix; said protein comprising a dimeric species having two oxidized subunits, the amino acid sequence of each said subunit comprising the amino acid sequence described by residues 334-430 of Seq. ID No.1, including allelic variants thereof.
20
15. The osteogenic protein of claim 14 wherein said amino acid sequence comprises the sequence described by residues 292-430 of Seq. ID No. 1, including allelic variants thereof.
25

16. An antibody capable of binding to an epitope on a protein comprising the amino acid sequence described by residues 334-430 of Seq. ID No. 1, including allelic variants thereof.

1/3

hOP-1	Ser	Thr	Gly	Ser	Lys	Gln	Arg	Ser	Gln
mOP-1	Gly	
	1				5				

hOP-1	Asn	Arg	Ser	Lys	Thr	Pro	Lys	Asn	Gln
mOP-1
	10				15				

hOP-1	Glu	Ala	Leu	Arg	Met	Ala	Asn	Val	Ala
mOP-1	Ser
	20				25				

hOP-1	Glu	Asn	Ser	Ser	Ser	Asp	Gln	Arg	Gln
mOP-1
	30					35			

hOP-1	Ala	Cys	Lys	Lys	His	Glu	Leu	Tyr	Val
mOP-1
	40					45			

hOP-1	Ser	Phe	Arg	Asp	Leu	Gly	Trp	Gln	Asp
mOP-1
	50								

hOP-1	Trp	Ile	Ile	Ala	Pro	Glu	Gly	Tyr	Ala
mOP-1
	55				60				

FIG. 1.1

2/3

hOP-1	Ala	Tyr	Tyr	Cys	Glu	Gly	Glu	Cys	Ala
mOP-1
			65				70		

hOP-1	Phe	Pro	Leu	Asn	Ser	Tyr	Met	Asn	Ala
mOP-1
			75				80		

hOP-1	Thr	Asn	His	Ala	Ile	Val	Gln	Thr	Leu
mOP-1
			85				90		

hOP-1	Val	His	Phe	Ile	Asn	Pro	Glu	Thr	Val
mOP-1	Asp
			95						

hOP-1	Pro	Lys	Pro	Cys	Cys	Ala	Pro	Thr	Gln
mOP-1
	100				105				

hOP-1	Leu	Asn	Ala	Ile	Ser	Val	Leu	Tyr	Phe
mOP-1
	110					115			

hOP-1	Asp	Asp	Ser	Ser	Asn	Val	Ile	Leu	Lys
mOP-1	Asp
	120						125		

FIG. 1.2

9/3

hOP-1	Lys	Tyr	Arg	Asn	Met	Val	Val	Arg
mOP-1
				130				135

hOP-1	Ala	Cys	Gly	Cys	His
mOP-1

FIG. 1.3

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 91/07654

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC5: C 07 K 15/06, C 12 N 15/12, A 61 K 37/02

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System	Classification Symbols
IPC5	C 07 K; C 12 N; A 61 K

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in Fields Searched⁸III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
P,X	EP, A2, 0416578 (TAKEDA CHEMICAL INDUSTRIES, LTD. ET AL) 13 March 1991, see e.g. fig. 2, fig. 4-3 ---	1-3,5- 16
P,X	Proc. Natl. Acad. Sci. USA, vol. 87, December 1990, A.J. Celeste et al: "Identification of transforming growth factor Beta family members present in bone-inductive protein purified from bovine bone ", see page 9843 - page 9847 see fig.1 --	1-16
X	WO, A1, 9011366 (GENETICS INSTITUTE, INC.) 4 October 1990, see especially table V --	1-16

^{*} Special categories of cited documents:¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

20th February 1992

Date of Mailing of this International Search Report

11.03.92

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	WO, A1, 9003733 (INTERNATIONAL GENETIC ENGINEERING, INC.) 19 April 1990, see the whole document --	1-16
X	WO, A1, 8909787 (CREATIVE BIOMOLECULES, INC.) 19 October 1989, see especially claim 23 --	1-2,5,7- 14,16
X	Chemical Abstracts, volume 113, no. 19, 5 November 1990, (Columbus, Ohio, US), Ozkaynak Engin et al: "OP-1 cDNA encodes an osteogenic protein in the TGF-beta family", see page 181, abstract 166493q, & EMBO J. 1990, 9(7), 2085-2093 -- -----	1-16

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.PCT/US 91/07654**

SA 53533

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
 The members are as contained in the European Patent Office EDP file on
 The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A2- 0416578	13/03/91	NONE		
WO-A1- 9011366	04/10/90	AU-D- EP-A-	5357790 0429570	22/10/90 05/06/91
WO-A1- 9003733	19/04/90	AU-B- AU-D- CA-A- EP-A-	615810 4488689 2000498 0394418	10/10/91 01/05/90 11/04/90 31/10/90
WO-A1- 8909787	19/10/89	AU-D- AU-D- EP-A- EP-A- JP-T- JP-T- US-A- WO-A- US-A- AU-D- EP-A- JP-T- US-A- WO-A-	3444989 3530589 0362367 0372031 3500655 3502579 4968590 89/09788 5011691 5174790 0411105 3504736 4975526 90/10018	03/11/89 03/11/89 11/04/90 13/06/90 14/02/91 13/06/91 06/11/90 19/10/89 30/04/91 26/09/90 06/02/91 17/10/91 04/12/90 07/09/90

For more details about this annex : see Official Journal of the European patent Office, No. 12/82